Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

Saved in:
Bibliographic Details
Published in:Blood cancer journal (New York) 2015-12, Vol.5 (12), p.e375-e375
Main Authors: Ravandi, F, Pigneux, A, DeAngelo, D J, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T, Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W, Smith, B D
Format: Article
Language:English
Subjects:
13/1
13/31
38/77
631/67/1990
631/67/1990/283
Adolescent
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Biomedical and Life Sciences
Biomedicine
Cancer Research
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - physiopathology
Hematology
Humans
Letter to the Editor
Middle Aged
Niacinamide - administration & dosage
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Niacinamide - pharmacokinetics
Oncology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c450t-a06b24024197d40be64f4ffb22701e019767b84171c05a54d3cd79f09f9f05793
cites cdi_FETCH-LOGICAL-c450t-a06b24024197d40be64f4ffb22701e019767b84171c05a54d3cd79f09f9f05793
container_end_page e375
container_issue 12
container_start_page e375
container_title Blood cancer journal (New York)
container_volume 5
creator Ravandi, F
Pigneux, A
DeAngelo, D J
Raffoux, E
Delaunay, J
Thomas, X
Kadia, T
Kantarjian, H
Scheuenpflug, J
Zhao, C
Guo, W
Smith, B D
description
doi_str_mv 10.1038/bcj.2015.103
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4735070</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4037680671</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-a06b24024197d40be64f4ffb22701e019767b84171c05a54d3cd79f09f9f05793</originalsourceid><addsrcrecordid>eNptkUFv3CAQhVHVqImS3HqukHrpIU7ABmMulapVmlZN1Ut7RmOM12xtcIFNlJ_Qfx2sTVebqByAeXx6zOgh9JaSS0qq5qrVm8uSUL5Ur9BJSRgreNXw1wf3Y3Qe44bkxWsqqXyDjsu65oJKeYL-rkbrrIbxAs8DhAm0_22dSVZjcN1e6x4cTFnrIAHufcBpMPj79Td6VWLrBtvalMXZThBNSLbNIp4hWeNSxPc2DRi6O3DadHgwEyQ_-nW2m2C0a5d1a-IZOuphjOb86TxFvz5f_1x9KW5_3HxdfbotNOMkFUDqtmSkZFSKjpHW1Kxnfd-WpSDUkKzWom0YFVQTDpx1le6E7Ins88aFrE7Rx53vvG0n0-ncYoBRzSE3Hx6UB6uevzg7qLW_U0xUnAiSDT48GQT_Z2tiUpON2owjOOO3UVHBpGwqXtUZff8C3fhtcHm8TDWs4bJii-HFjtLBxxhMv2-GErXErHLMaol5qTL-7nCAPfwv1AwUOyDmJ7c24eDX_xk-Arwqs2w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784859340</pqid></control><display><type>article</type><title>Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Ravandi, F ; Pigneux, A ; DeAngelo, D J ; Raffoux, E ; Delaunay, J ; Thomas, X ; Kadia, T ; Kantarjian, H ; Scheuenpflug, J ; Zhao, C ; Guo, W ; Smith, B D</creator><creatorcontrib>Ravandi, F ; Pigneux, A ; DeAngelo, D J ; Raffoux, E ; Delaunay, J ; Thomas, X ; Kadia, T ; Kantarjian, H ; Scheuenpflug, J ; Zhao, C ; Guo, W ; Smith, B D</creatorcontrib><identifier>ISSN: 2044-5385</identifier><identifier>EISSN: 2044-5385</identifier><identifier>DOI: 10.1038/bcj.2015.103</identifier><identifier>PMID: 26657199</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13/1 ; 13/31 ; 38/77 ; 631/67/1990 ; 631/67/1990/283 ; Adolescent ; Adult ; Aged ; Antineoplastic Agents - administration &amp; dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacokinetics ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Hematologic Neoplasms - drug therapy ; Hematologic Neoplasms - physiopathology ; Hematology ; Humans ; Letter to the Editor ; Middle Aged ; Niacinamide - administration &amp; dosage ; Niacinamide - adverse effects ; Niacinamide - analogs &amp; derivatives ; Niacinamide - pharmacokinetics ; Oncology ; Young Adult</subject><ispartof>Blood cancer journal (New York), 2015-12, Vol.5 (12), p.e375-e375</ispartof><rights>The Author(s) 2015</rights><rights>Copyright Nature Publishing Group Dec 2015</rights><rights>Copyright © 2015 Macmillan Publishers Limited 2015 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-a06b24024197d40be64f4ffb22701e019767b84171c05a54d3cd79f09f9f05793</citedby><cites>FETCH-LOGICAL-c450t-a06b24024197d40be64f4ffb22701e019767b84171c05a54d3cd79f09f9f05793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1784859340/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1784859340?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26657199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ravandi, F</creatorcontrib><creatorcontrib>Pigneux, A</creatorcontrib><creatorcontrib>DeAngelo, D J</creatorcontrib><creatorcontrib>Raffoux, E</creatorcontrib><creatorcontrib>Delaunay, J</creatorcontrib><creatorcontrib>Thomas, X</creatorcontrib><creatorcontrib>Kadia, T</creatorcontrib><creatorcontrib>Kantarjian, H</creatorcontrib><creatorcontrib>Scheuenpflug, J</creatorcontrib><creatorcontrib>Zhao, C</creatorcontrib><creatorcontrib>Guo, W</creatorcontrib><creatorcontrib>Smith, B D</creatorcontrib><title>Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies</title><title>Blood cancer journal (New York)</title><addtitle>Blood Cancer Journal</addtitle><addtitle>Blood Cancer J</addtitle><subject>13/1</subject><subject>13/31</subject><subject>38/77</subject><subject>631/67/1990</subject><subject>631/67/1990/283</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Agents - administration &amp; dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Hematologic Neoplasms - physiopathology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Letter to the Editor</subject><subject>Middle Aged</subject><subject>Niacinamide - administration &amp; dosage</subject><subject>Niacinamide - adverse effects</subject><subject>Niacinamide - analogs &amp; derivatives</subject><subject>Niacinamide - pharmacokinetics</subject><subject>Oncology</subject><subject>Young Adult</subject><issn>2044-5385</issn><issn>2044-5385</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkUFv3CAQhVHVqImS3HqukHrpIU7ABmMulapVmlZN1Ut7RmOM12xtcIFNlJ_Qfx2sTVebqByAeXx6zOgh9JaSS0qq5qrVm8uSUL5Ur9BJSRgreNXw1wf3Y3Qe44bkxWsqqXyDjsu65oJKeYL-rkbrrIbxAs8DhAm0_22dSVZjcN1e6x4cTFnrIAHufcBpMPj79Td6VWLrBtvalMXZThBNSLbNIp4hWeNSxPc2DRi6O3DadHgwEyQ_-nW2m2C0a5d1a-IZOuphjOb86TxFvz5f_1x9KW5_3HxdfbotNOMkFUDqtmSkZFSKjpHW1Kxnfd-WpSDUkKzWom0YFVQTDpx1le6E7Ins88aFrE7Rx53vvG0n0-ncYoBRzSE3Hx6UB6uevzg7qLW_U0xUnAiSDT48GQT_Z2tiUpON2owjOOO3UVHBpGwqXtUZff8C3fhtcHm8TDWs4bJii-HFjtLBxxhMv2-GErXErHLMaol5qTL-7nCAPfwv1AwUOyDmJ7c24eDX_xk-Arwqs2w</recordid><startdate>20151211</startdate><enddate>20151211</enddate><creator>Ravandi, F</creator><creator>Pigneux, A</creator><creator>DeAngelo, D J</creator><creator>Raffoux, E</creator><creator>Delaunay, J</creator><creator>Thomas, X</creator><creator>Kadia, T</creator><creator>Kantarjian, H</creator><creator>Scheuenpflug, J</creator><creator>Zhao, C</creator><creator>Guo, W</creator><creator>Smith, B D</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20151211</creationdate><title>Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies</title><author>Ravandi, F ; Pigneux, A ; DeAngelo, D J ; Raffoux, E ; Delaunay, J ; Thomas, X ; Kadia, T ; Kantarjian, H ; Scheuenpflug, J ; Zhao, C ; Guo, W ; Smith, B D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-a06b24024197d40be64f4ffb22701e019767b84171c05a54d3cd79f09f9f05793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>13/1</topic><topic>13/31</topic><topic>38/77</topic><topic>631/67/1990</topic><topic>631/67/1990/283</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Agents - administration &amp; dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Hematologic Neoplasms - physiopathology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Letter to the Editor</topic><topic>Middle Aged</topic><topic>Niacinamide - administration &amp; dosage</topic><topic>Niacinamide - adverse effects</topic><topic>Niacinamide - analogs &amp; derivatives</topic><topic>Niacinamide - pharmacokinetics</topic><topic>Oncology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ravandi, F</creatorcontrib><creatorcontrib>Pigneux, A</creatorcontrib><creatorcontrib>DeAngelo, D J</creatorcontrib><creatorcontrib>Raffoux, E</creatorcontrib><creatorcontrib>Delaunay, J</creatorcontrib><creatorcontrib>Thomas, X</creatorcontrib><creatorcontrib>Kadia, T</creatorcontrib><creatorcontrib>Kantarjian, H</creatorcontrib><creatorcontrib>Scheuenpflug, J</creatorcontrib><creatorcontrib>Zhao, C</creatorcontrib><creatorcontrib>Guo, W</creatorcontrib><creatorcontrib>Smith, B D</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood cancer journal (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ravandi, F</au><au>Pigneux, A</au><au>DeAngelo, D J</au><au>Raffoux, E</au><au>Delaunay, J</au><au>Thomas, X</au><au>Kadia, T</au><au>Kantarjian, H</au><au>Scheuenpflug, J</au><au>Zhao, C</au><au>Guo, W</au><au>Smith, B D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies</atitle><jtitle>Blood cancer journal (New York)</jtitle><stitle>Blood Cancer Journal</stitle><addtitle>Blood Cancer J</addtitle><date>2015-12-11</date><risdate>2015</risdate><volume>5</volume><issue>12</issue><spage>e375</spage><epage>e375</epage><pages>e375-e375</pages><issn>2044-5385</issn><eissn>2044-5385</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26657199</pmid><doi>10.1038/bcj.2015.103</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2044-5385
ispartof Blood cancer journal (New York), 2015-12, Vol.5 (12), p.e375-e375
issn 2044-5385
2044-5385
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4735070
source Open Access: PubMed Central; Publicly Available Content Database; Springer Nature - nature.com Journals - Fully Open Access
subjects 13/1
13/31
38/77
631/67/1990
631/67/1990/283
Adolescent
Adult
Aged
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - adverse effects
Antineoplastic Agents - pharmacokinetics
Biomedical and Life Sciences
Biomedicine
Cancer Research
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - physiopathology
Hematology
Humans
Letter to the Editor
Middle Aged
Niacinamide - administration & dosage
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Niacinamide - pharmacokinetics
Oncology
Young Adult
title Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A25%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical,%20pharmacokinetic%20and%20pharmacodynamic%20data%20for%20the%20MEK1/2%20inhibitor%20pimasertib%20in%20patients%20with%20advanced%20hematologic%20malignancies&rft.jtitle=Blood%20cancer%20journal%20(New%20York)&rft.au=Ravandi,%20F&rft.date=2015-12-11&rft.volume=5&rft.issue=12&rft.spage=e375&rft.epage=e375&rft.pages=e375-e375&rft.issn=2044-5385&rft.eissn=2044-5385&rft_id=info:doi/10.1038/bcj.2015.103&rft_dat=%3Cproquest_pubme%3E4037680671%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-a06b24024197d40be64f4ffb22701e019767b84171c05a54d3cd79f09f9f05793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1784859340&rft_id=info:pmid/26657199&rfr_iscdi=true